Related Experiment Video
Updated: May 10, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding
Taymaa May1, Junzheng Yang, Melina Shoni
1Department of Obstetrics/Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Introduction:
Ovarian cancer is the leading cause of mortality from gynecological malignancy despite advancements in novel therapeutics. We have recently demonstrated that the transcriptional co-repressor C-terminal binding protein 2 (CtBP2) is overexpressed in epithelial ovarian carcinoma.
Materials And Methods:
Reverse-transcribed cDNA from CtBP2 wild-type and knockdown ovarian cancer cell lines was hybridized to Affymetrix Gene 1.0 ST microarrays, and differentially expressed genes were studied. Immunohistochemical analysis of CtBP2 and BRCA1 staining of ovarian tissues was performed. Chromatin immunoprecipitation (ChIP) and luciferase assays were carried out. The effect of the drugs 4-methylthio-2-oxobutyric acid (MTOB) and poly(ADP-ribose) polymerase (PARP) inhibitor Olaparib on CtBP2 wild-type and knockdown cell lines was examined using methylthiazol tetrazolium assays and an xCELLigence System.
Results:
Eighty-five genes involved in DNA repair, mitotic checkpoint, nucleosome assembly, and the BRCA1 network were differentially regulated by CtBP2 expression. ChIP and luciferase reporter assays using a BRCA1 promoter-regulated luciferase construct indicated that the CtBP2 complex binds the BRCA1 promoter and represses BRCA1 transcription. Immunohistochemistry illustrated a significant inverse CtBP2 and BRCA1 expression in a panel of malignant ovarian tumor tissues. The CtBP2 inhibitor MTOB suppressed ovarian cancer cell survival in a CtBP2-dependent manner. Ovarian cancer cells with CtBP2 knockdown did not display increased sensitivity to the PARP inhibitor Olaparib.
Conclusion:
CtBP2 is an ovarian cancer oncogene that may play a significant role in epigenetically silencing BRCA1 function in sporadic epithelial ovarian cancer. CtBP2-specific inhibitors, such as MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.
Insights
C-terminal binding protein 2 (CtBP2) is an oncogene in ovarian cancer that silences BRCA1. Inhibiting CtBP2 with MTOB may be an effective treatment for ovarian cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer remains a leading cause of gynecological cancer mortality.
- C-terminal binding protein 2 (CtBP2) is overexpressed in epithelial ovarian carcinoma.
Purpose of the Study:
- To investigate the role of CtBP2 in ovarian cancer pathogenesis.
- To explore CtBP2's regulation of BRCA1.
- To evaluate CtBP2 inhibitors as a potential therapeutic strategy.
Main Methods:
- Gene expression analysis using microarrays.
- Chromatin immunoprecipitation (ChIP) and luciferase assays.
- Immunohistochemical analysis of ovarian tumor tissues.
- Drug sensitivity assays with CtBP2 inhibitor MTOB and PARP inhibitor Olaparib.
Main Results:
- CtBP2 differentially regulates 85 genes, including those in the BRCA1 network.
- CtBP2 binds to and represses the BRCA1 promoter.
- Inverse correlation between CtBP2 and BRCA1 expression in ovarian tumors.
- CtBP2 inhibitor MTOB suppresses ovarian cancer cell survival.
Conclusions:
- CtBP2 acts as an oncogene in ovarian cancer by epigenetically silencing BRCA1.
- CtBP2-specific inhibitors like MTOB show promise as adjunct therapies for CtBP2-positive ovarian cancer.
More Related Videos
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
08:53Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation